| Trehan [23]. Malawi, 2010 |
AMX vs No AB
|
Retrospective Cohort: 2 centres only; Uncomplicated SAM (all); HIV% = ? |
n1:498 n2:1955, 6–59 mths |
Recovery worse at 4 wks in AMX group vs no-AMX (40% vs 71%); No difference in recovery at 12 wks (84% vs 86%) p>0.05; Risk of bias due to design and baseline weight+age differences. |
2/High |
| Manary [24], Malawi, 2011 |
Cefdinir (CEF) vs AMX vs Placebo
|
Randomized double-blinded placebo-controlled: Uncomplicated SAM (all); HIV+ = 188; Tested = 874 (21.5%); Mother HIV = 388 |
2767, 6–59 mths |
Superiority CEF>AMX *>placebo**; Nutritional recovery at 12 wks: 90.9%, 87.7%, 85.1% p* = 0.02 p** = 0.001; Mortality: 4.1%, 4.8%, 7.4% (p = .003); Shorter time to recovery; Risk of BIAS: HIV-NEG not analysed separately. |
4/High (But still not in peer-reviewed journal) |
| Dubray [25], Sudan, 2008 |
Ceftriaxone (CRO) vs (2days-IM) AMX (5days-Oral) |
RCT non-blinded: Complicated & uncomplicated SAM; HIV% = ? |
458, 6–59 mths |
No difference in Cured: AMX:70%/CRO:74.6% (p = 0.27); Mortality: AMX3.9%/CRO3.1% (p = 0.67). Cost: 0.2 vs 1.6 Euros (10 kg child); Risk of Bias: complicated SAM included+low power. |
3/Medium |
